Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32466-1/fulltext